Elsevier

The Lancet

Volume 357, Issue 9251, 20 January 2001, Pages 223-224
The Lancet

Viewpoint
What can be achieved with an HIV vaccine?

https://doi.org/10.1016/S0140-6736(00)03601-1Get rights and content

References (18)

There are more references available in the full text version of this article.

Cited by (23)

  • HIV prevention risks for Black women in Canada

    2009, Social Science and Medicine
    Citation Excerpt :

    HIV vaccines may be a woman-controlled method, but consequences attached to their use can still create barriers. In addition, HIV vaccines will only be effective if populations are still using existing prevention methods like education, HIV testing and safer sex practices (Levy, 2001). Therefore, preparation for the future requires gathering information to build proactive strategies that will facilitate use of all available HIV prevention.

  • AIDS vaccine: Efficacy, safety and ethics

    2008, Vaccine
    Citation Excerpt :

    Yet only one AIDS vaccine has reached the Phase III efficacy trial in humans. In the early stage of AIDS vaccine development, scientists had estimated that efficacy of the gp120 vaccine would be between 30 and 50%, or even lower; and subsequent clinical trials did not confirmed these predictions [4]. In this situation, developers of AIDS vaccine shifted from vaccines inducing “sterile immunity” toward a more realistic goal of developing less effective vaccines that could reduce the risk of transmission by decreasing the viral load.

  • What can HIV vaccine trials teach us about future HIV vaccine dissemination?

    2008, Vaccine
    Citation Excerpt :

    These misconceptions reinforce the importance of ensuring that trial participants understand the necessarily uncertain nature of experimental vaccine efficacy as well as the possibility of receiving a placebo. In terms of the dissemination of future HIV vaccines, evaluation of approaches to providing education around uncertain vaccine efficacy in the context of clinical trials may provide data to support educational interventions to promote behavioral prevention in the likely scenario of deployment of a partially efficacious vaccine [15,23,24]. Similarly, materials that prove effective in educating trial participants about false-positives, vaccine side effects and the impossibility of vaccine-induced HIV infection may build evidence for interventions to support future HIV vaccine dissemination.

View all citing articles on Scopus
View full text